LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Home・Akcijų sąrašas・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Uždarymo kaina

1.39 -0.71

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.35

Max

1.43

Pagrindiniai rodikliai
By Trading Economics
Pajamos	183K -27M
Pelnas, tenkantis vienai akcijai	-0.37
Pelno marža	-176.706
Darbuotojai	166
EBITDA	9.4M -27M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+371.43% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	6.7M 102M
Ankstesnė atidarymo kaina	2.1
Ankstesnė uždarymo kaina	1.39

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

1.23 / 1.45 Palaikymas ir pasipriešinimas

Zentalis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-15 17:39; UTC

Pagrindinės rinkos jėgos

Vanda Pharmaceuticals Rises on FDA Biologics License Application

2025-12-15 23:44; UTC

Rinkos pokalbiai

Gold Steady Ahead of U.S. Employment Report -- Market Talk

2025-12-15 23:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-15 23:38; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

2025-12-15 22:19; UTC

Rinkos pokalbiai

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

2025-12-15 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-15 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

2025-12-15 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

2025-12-15 21:28; UTC

Įsigijimai, susijungimai, perėmimai

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

2025-12-15 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

2025-12-15 21:23; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

2025-12-15 21:23; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

2025-12-15 21:23; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

2025-12-15 21:22; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

2025-12-15 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

2025-12-15 21:15; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Completes Acquisition Of Moveworks >NOW

2025-12-15 21:00; UTC

Įsigijimai, susijungimai, perėmimai

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

2025-12-15 20:57; UTC

Įsigijimai, susijungimai, perėmimai

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

2025-12-15 20:36; UTC

Rinkos pokalbiai

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

2025-12-15 20:31; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

2025-12-15 20:27; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

2025-12-15 20:15; UTC

Rinkos pokalbiai

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

2025-12-15 19:22; UTC

Rinkos pokalbiai

Gold and Silver Gain to Start Week -- Market Talk

2025-12-15 18:37; UTC

Rinkos pokalbiai

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

2025-12-15 18:29; UTC

Rinkos pokalbiai

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

2025-12-15 17:58; UTC

Rinkos pokalbiai

Canada Housing Market In Search Of a Bottom -- Market Talk

2025-12-15 17:36; UTC

Rinkos pokalbiai

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

2025-12-15 17:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-15 17:36; UTC

Uždarbis

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

2025-12-15 17:30; UTC

Įsigijimai, susijungimai, perėmimai

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Zentalis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

371.43% į viršų

12 mėnesių prognozė

Vidutinis 6.6 USD 371.43%

Aukščiausias 10 USD

Žemiausias 4 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zentalis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Zentalis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.23 / 1.45Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.